Lung Cancer Chemoradiation: Predictors of Survival

肺癌放化疗：生存的预测因素

• 批准号: 7939475
• 负责人: Xifeng Wu
• 金额: $ 24.32万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-28 至 2011-09-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7939475
• 关键词: Acute; Apoptotic; Base Excision Repairs; Biological Assay; Body Weight decreased; Cancer Patient; Carboplatin; Cell Cycle; Cell Cycle Regulation; Cell Line; Cells; Characteristics; Cisplatin; Clinical; Comet Assay; DNA Repair Pathway; Data; Demographic Factors; Development; Diagnosis; Dietary intake; Disease; Dose; Dose-Limiting; Double Strand Break Repair; Drug resistance; Enrollment; Event; Excision Repair; Exhibits; Family Cancer History; Frequencies; Genes; Genetic; Genetic Polymorphism; Genotype; Histology; In Vitro; Individual; Interview; Lymphocyte; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Medical History; Micronutrients; Modeling; Molecular; Morbidity - disease rate; Multi-Drug Resistance; Non-Small-Cell Lung Carcinoma; Nucleotide Excision Repair; Outcome; Paclitaxel; Pathway interactions; Patients; Performance Status; Pharmaceutical Preparations; Phenotype; Platinum; Platinum Compounds; Platinum adduct; Predisposition; Quality of life; Radiation; Radiation Toxicity; Radiation induced damage; Radiation therapy; Relapse; Research; Research Infrastructure; Resistance; Risk; Risk Assessment; Sampling; Smoking; Smoking History; Staging; Testing; Therapeutic Index; Toxic effect; Translating; Treatment Efficacy; Variant; analog; base; cancer therapy; chemotherapy; clinically relevant; clinically significant; cohort; dosage; drug efficacy; drug metabolism; drug sensitivity; epidemiologic data; experience; follow-up; gene therapy; high risk; improved; insight; outcome forecast; prognostic; prospective; repaired; resistance mechanism; response; tumor; uptake

DESCRIPTION (provided by applicant): The efficacy of treatment for non-small cell lung cancer (NSCLC) has improved only marginally over the past few decades. Chemoradiotherapy continues to have a narrow therapeutic index, and response rates are unpredictable, even after controlling for the known predictors of stage, histology, grade, and performance status. Drug resistance presents a major obstacle in NSCLC treatment. Platinum agents, specifically cisplatin and carboplatin, are the cornerstones of NSCLC therapy. Radiation induced toxicity is similarly unpredictable and dose limiting. Data from in vitro studies show that radioresistance is associated with poor prognosis and that, compared to radioresistant lines, radiosensitive cell lines exhibit greater initial damage and repair this damage more slowly. Cellular events that are modulated by sets of interacting genes may partly explain such unpredictable outcomes. We hypothesized that interindividual genetic differences impact the efficacy and toxicity of platinum-based therapy and that this genetic information can be used to predict individual drug response. In this proposal, we will build upon an existing case ascertainment infrastructure to achieve the following specific aims: 1. We will construct a well-characterized cohort of 1400 advanced NSCLC (inoperable stages III and IV) patients treated with platinum drugs combined with other agents + radiation. This sample will consist of 800 patients prospectively enrolled and 600 patients retrospectively identified through participation in our ongoing studies. By personal interview and medical chart review, we have obtained or will obtain detailed baseline information on smoking history, dietary intake, family cancer history, previous medical history, weight loss, performance status, tumor characteristics, treatment toxicity and efficacy, and complete patient follow up data. 2. To evaluate the intrinsic repair capacity of the prospective cases, we will use two functional lymphocyte-based comet assays, the fir it of which assesses basic excision repair (BER) and double-strand break repair (DSB) of radiation-induced damage, and the second of winch assesses mainly nucleotide excision repair (NER) of platinum-induced damage. Through these assays, we will test the hypothesis that the host's intrinsic repair capacity influences drug sensitivity. Specifically, we hypothesize that reduced NER capacity is associated with improved response to platinum therapy (due to decreased ability to repair platinum adducts). Further, we hypothesize that reduced BER and/or DSB repair capacity, because it translates to a decreased ability to repair damage to rapidly dividing cells, is associated with higher risk of acute and late-term radiation toxicity; however, reduced BER and/or DSB repair capacity is conversely associated with improved survival. 3. In parallel with the phenotypic assays, we will assume a pathway-based approach in all 1400 patients to evaluate frequencies of polymorphisms in genes involved in DNA repair pathways, specifically NER, BER, and DSB. We will also evaluate frequencies of polymorphisms in pathways relevant for the activity or disposition of platinum analogs and taxols, including drug metabolism, multidrug resistance, cellular uptake, and select genes in cell cycle control and apoptotic pathways. We will test the hypothesis that therapy response, resistance, and toxicity are modulated by variants in multiple relevant genes. We will also test the hypothesis that there are correlations between the repair genotypes and the phenotype data from Aim 2. 4. We will integrate clinical and epidemiologic data - such as smoking at diagnosis and treatment initiation, demographic factors, poor dietary intake of select micronutrients, weight loss, performance status, and tumor characteristics - with the genetic data from the studies described above. We will develop a quantitative multivariate risk assessment model that will incorporate and prioritize these relevant epidemiologic and molecular predictors of outcome. The unifying theme of this study is that intrinsic differences in the susceptibility of cells to the genotoxic effects of radiotherapy and chemotherapy modulate toxicity and outcome. This multivariate prognostic study could have long-term prognostic potential by allowing greater individualization of therapy, based on the genetic makeup of the patient, thereby both increasing efficacy and reducing morbidity.

描述(由申请人提供)：在过去的几十年里，非小细胞肺癌(NSCLC)的治疗效果只有轻微的改善。即使在控制了分期、组织学、分级和表现状态的已知预测因素之后，放化疗仍然有一个狭窄的治疗指数，并且应答率是不可预测的。耐药性是非小细胞肺癌治疗的主要障碍。铂类药物，特别是顺铂和卡铂，是非小细胞肺癌治疗的基石。辐射引起的毒性同样是不可预测的，而且受到剂量限制。来自体外研究的数据表明，辐射抵抗与不良预后有关，与辐射抵抗株相比，辐射敏感细胞株表现出更大的初始损伤，修复这种损伤的速度更慢。由一组相互作用的基因调节的细胞事件可能在一定程度上解释了这种不可预测的结果。我们假设个体间的遗传差异会影响以铂为基础的治疗的疗效和毒性，并且这种遗传信息可以用于预测个体的药物反应。在这项建议中，我们将建立一个现有的病例确定基础设施，以实现以下具体目标：1.我们将建立一个由1400名晚期非小细胞肺癌(不能手术的III和IV期)患者组成的特征良好的队列，这些患者接受铂类药物联合其他药物+放射治疗。这个样本将包括800名前瞻性登记的患者和600名通过参与我们正在进行的研究而回顾确定的患者。通过个人访谈和病历查阅，我们已经或将获得详细的基线信息，包括吸烟史、饮食摄入量、癌症家族史、既往病史、体重减轻、表现状况、肿瘤特征、治疗毒性和疗效，以及完整的患者随访数据。2.为了评估潜在病例的内在修复能力，我们将使用两种基于淋巴细胞的彗星试验，第一种是评估放射损伤的基本切除修复(BER)和双链断裂修复(DSB)，第二种是评估铂损伤的核苷酸切除修复(NER)。通过这些检测，我们将检验宿主的内在修复能力影响药物敏感性的假设。具体地说，我们假设NER能力的降低与铂治疗反应的改善有关(由于修复铂加合物的能力降低)。此外，我们假设，BER和/或DSB修复能力降低，因为它转化为对快速分裂细胞的损伤修复能力降低，与急性和晚期辐射毒性的风险更高相关；然而，BER和/或DSB修复能力降低与生存改善相反。3.在表型分析的同时，我们将在所有1400名患者中采用基于途径的方法来评估涉及DNA修复途径的基因的多态频率，特别是NER、BER和DSB。我们还将评估与铂类似物和紫杉醇活性或处置相关的途径的多态频率，包括药物代谢、多药耐药、细胞摄取，以及细胞周期控制和凋亡途径中的选择基因。我们将检验这一假设，即治疗反应、耐药性和毒性是由多个相关基因的变异调节的。我们还将检验修复基因与AIM 2.4的表型数据之间存在相关性的假设。我们将把临床和流行病学数据--如诊断和治疗开始时吸烟、人口统计因素、特定微量营养素的饮食摄入不良、体重减轻、表现状态和肿瘤特征--与上述研究的基因数据整合在一起。我们将开发一个定量的多变量风险评估模型，该模型将纳入并优先考虑这些相关的流行病学和分子结果预测因素。这项研究的统一主题是，细胞对放射和化疗的基因毒性效应的敏感性的内在差异调节了毒性和结果。这项多变量预后研究可以根据患者的基因构成进行更大程度的个体化治疗，从而提高疗效和降低发病率，从而具有长期预后潜力。